Synthetic PPARγ ligands are generally well-tolerated and nontoxic; however, multiple groups have reported adverse cardiovascular events associated with PPARγ ligands, including myocardial hypertrophy and congestive heart failure due to plasma volume expansion and edema, in humans and animal models [110–112]. The gene discussed is PPARG; the disease is cardiac hypertrophy.